Clinical Trial Results: Afatinib in Metastatic Esophageal Squamous Cell Carcinoma
Key Findings:
Preclinical data demonstrated promising antitumor activity of afatinib in EGFR-overexpressing ESCC.
Phase II trial showed a confirmed objective response rate (ORR) of 39% and a median overall survival of 7.8 months in pretreated metastatic ESCC patients with EGFR overexpression.
Transcriptome analysis revealed a negative association between NTRK2 and afatinib sensitivity, suggesting its potential as a predictive biomarker.
Knocking down or inhibiting NTRK2 sensitized ESCC cells to afatinib treatment.
Practical Solutions and Value:
These findings offer insights into molecular factors underlying afatinib resistance and highlight its potential as an important treatment for metastatic ESCC patients.
Integration of AI-driven platforms like DocSym can consolidate clinical standards, protocols, and research, facilitating easier access to knowledge for clinicians.
Mobile apps can streamline operations, support scheduling, monitoring treatments, and telemedicine, ultimately improving patient care and expanding digital services.
AI can enhance clinic workflows, reduce paper routines, and improve patient outcomes.
For more information, visit aidevmd.com.
